Jefferies analyst Brian Tanquilut raised the firm’s price target on RadNet (RDNT) to $100 from $82 and keeps a Buy rating on the shares. Ongoing strength in broader healthcare utilization, along with a site of service shift from hospitals to freestanding centers, should drive sustained healthy volumes. Meanwhile, deployment of RadNet’s $750M of cash on its balance sheet toward M&A should boost growth and earnings power, the analyst tells investors.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDNT:
- RadNet price target raised to $85 from $79 at Barclays
- RadNet’s DeepHealth launches new AI-powered solutions at RSNA 2024
- RadNet’s DeepHealth expands FDA clearance for SmartMammo solution
- RadNet price target raised to $94 from $80 at Truist
- RadNet’s DeepHealth expands FDA clearance for SmartMammo solutionGE